Peripheral Artery Disease

Peripheral artery disease (PAD) involves atherosclerosis mainly in the extremities, especially in the legs and feet that lead to ischemia. Untreated, PAD can progress to critical limb ischemia (CLI), also called chronic limb-threatening ischemia (CLTI), which will lead to foot or leg amputation. The mortality rate for these CLI amputees is 70% within three years. There is currently an epidemic of PAD and CLI in the U.S. The majority of patients are defined by health disparities concentrated in the Black, Latino, Native American populations in both rural and low-income urban areas. A large number of PAD patients have other comorbities, with diabetes being one a primary issue.

RSS icon

Boston Scientific gains FDA approval for Ranger drug-coated balloon

The newly approved solution was designed for the treatment of patients with PAD in the superficial femoral artery and proximal popliteal artery.

Thumbnail

Advocates applaud legislation that would improve coverage for peripheral artery disease screening

If signed into law, the bill would improve coverage for screening for both Medicare and Medicaid beneficiaries. 

Thumbnail

'A missed opportunity': Statin use low among patients with peripheral artery disease

Researchers tracked statin use among patients with peripheral artery disease, cerebrovascular disease and coronary heart disease.

Thumbnail

Another way work-related stress can impact your cardiovascular health

Work-related stress is associated with an increased risk of peripheral artery disease (PAD), according to a new study published in the Journal of the American Heart Association.

Thumbnail

Endovascular-first approach boosts amputation-free survival in patients with critical limb ischemia

Patients with critical limb ischemia might be better off if they opt for endovascular-first treatment over an open surgical bypass, a Circulation: Cardiovascular Quality and Outcomes study suggests.

New data from the IMPERIAL clinical program demonstrates ELUVIA more effective in diabetic patients

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

Appropriate use criteria give edge to endovascular therapies for treating PAD

Several professional societies collaborated to release appropriate use criteria for peripheral artery intervention (PAI), a field the authors acknowledged still has an emerging evidence base that is likely to change these recommendations in the future.

Thumbnail

CLI revascularization techniques are more cost-effective, associated with longer survival than amputation

Revascularization techniques to treat primary critical limb ischemia (CLI) may be more cost-effective and associated with longer survival than primary major amputation, according to new research published in the Journal of the American Heart Association.

Displaying 49 - 56 of 68

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.